Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
521. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
View |
522. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
523. |
ECCT/25/05/07 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Prof Jessie Githanga Site(s) in Kenya 1. Gertrudes Childrens Hospital (Nairobi City county) 2. KEMRI Kondele Children\'s Hospital (Kisumu county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 5. KEMRI WALTER REED KERICHO (Kericho county) 6. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 7. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) |
View |
524. |
ECCT/25/05/12 | SAFIRE A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR) |
View |
525. |
ECCT/25/05/13 | IVI CCV 002 A Phase II, randomized, controlled, age-descending study in adults and children to evaluate the safety and immunogenicity of the OSP:rTTHc Cholera Conjugate Vaccine in cholera-endemic region |
Principal Investigator(s) 1. Walter Jaoko Site(s) in Kenya KAVI - Institute of Clinical Research, University of Nairobi |
View |